When focusing on the independent predictive effect of CD34+ CAFs in stage I‐III NSCLC, whether CAFs influence EMT along with lymphatic and metastatic spread, as proposed in vitro by Kim et al. 25 should be investigated, In summary, the findings are consistent with available data for CAFs in malignant tissues26, 27, 28, 30, 31, 44, 45, 46 and contribute to our understanding of CAFs in NSCLC prognosis. The gene discussed is CD34; the disease is non-small cell lung carcinoma.